Quality & Transparency: Making Certificates of Analysis available to every Hims & Hers customer

July 31, 2024

Everyone who interacts with medication (manufacturers, distributors, healthcare providers, and patients) should have the materials they need to have confidence in the medication's quality.

download button

Everyone who interacts with medication (manufacturers, distributors, healthcare providers, and patients) should have the materials they need to have confidence in the medication's quality.

Download image
In August, Certificates of Analysis on the compounded GLP-1 medications available through Hims & Hers will be accessible to customers, in an effort to introduce a higher level of transparency that helps our customers understand what is in the medications they receive, as well as how to understand the high quality standards we hold for ourselves.

A Certificate of Analysis (COA) is a document issued by a 503B outsourcing facility or laboratory that provides detailed information to ensure that the medication meets regulatory standards and the ingredients are what they say they are. Think of a COA as a report card for a specific batch of medication: it details the tests conducted on a medication, the achieved results, and the comparison to benchmarks established by the United States Pharmacopeia (USP)

We are sharing these certificates for each customer so that everyone who interacts with the medication (manufacturers, distributors, healthcare providers, and patients) can have confidence in the medication's quality.

At Hims & Hers, we’re a partner to every customer on their health and wellness journey – and  we’re committed to the safety of every customer through each step along the way. We think it is critical that customers know the quality of the medication they are receiving so we’re making the COAs for the compounded GLP-1 medications readily available upon request for customers who are looking to verify the quality of their medications. Here’s how to read a COA, which is typically split into three parts:

Identification

The COA will provide identifying information like the medication's name and batch or lot number, so the medication can be traced and authenticated. This section will also include the date it was made, the expiration date, and required storage conditions, as well as the name and address of the manufacturer.

Click here to view the full COA.
Specifications & Testing Results

Following the identification section, the COA will outline the specific standards a medication must meet according to regulatory requirements, typically set by the USP. These specifications are the standard against which the testing results are measured. In a table, the results of tests performed on the medication are available in the context of the standards the medication is supposed to meet:

Click here to view the full COA.

COAs for compounded GLP-1 injections available through Hims & Hers look at 9 different criteria, as determined by the USP:

  • Description: This determines simply how the medication should look. For compounded GLP injections, it should be a clear, colorless solution.
  • Identification A: This test identifies that the medication is actually what it says it is (in this case, Semaglutide) using a very sophisticated piece of equipment called High-Performance Liquid Chromatography (HPLC). 
  • pH: Using the USP 791 required method, this test tells us how acidic or basic the medication is. For compounded GLP-1s, the pH is required to be somewhere between 7.0 and 7.8. If the batch tests anywhere within the range, it passes.
  • Container Content: This test confirms the amount of liquid inside the vial. The contents should not be less than what is on the label. (You’ll see the acronyms NLT or NMT used in the specification field for some tests, which means “not less than” and “not more than.”) 
  • Particulate matter: This test ensures the medication doesn’t contain objectionable particles through a method called light obscuration analysis, which counts any particles as the medication is passed through a light source and detector. This method can measure particles even smaller than the human eye can see.
  • Assay: Assay is another word for potency or strength. This test determines if the medication meets the strength listed on the label, which must be between 90% to 110%.
  • Benzyl alcohol content: This test detects and quantifies the amount of benzyl alcohol present in the solution. Benzyl Alcohol is the ingredient that makes a vial multi-dose because it protects the medication from contamination when a customer injects a needle into the vial several times. 
  • Bacterial endotoxins test: Bacterial endotoxins are released when bacteria die off and leave behind the cellular remnants that can cause adverse reactions like fever. This test ensures that an unsafe amount of these endotoxins are not present in the medication.
  • Sterility test: Sterility, as defined by USP 71, is critical for sterile injectable medications in order to keep patients safe. A manufacturer cannot claim a medication has been properly tested without following the USP 71 standard of process control and microbiological quality of a medication. For compounded GLP-1 injections (and all sterile injections!), the gold standard is a test result indicating no microbial growth.
Approval and Certification:

The COA is signed and dated at the end of a document by an authorized expert, like a quality assurance manager or laboratory technician, certifying that the medication meets the required specifications.

Click here to view the full COA.
Accessing a COA

Starting later in August, you can access your COA at the Customer Safety Portal at hims.com/trust-and-safety/weight-loss/coa and forhers.com/trust-and-safety/weight-loss/coa.

Our responsibility to our customers extends beyond just providing the safest access to care possible – we believe it includes being transparent about what is in the medications customers are sent. Customers should know what to look for in order to confirm they are receiving medications from licensed, reputable suppliers who comply with critical legal requirements. 

For us, it’s not enough to say we’re completing a rigorous process. We want to empower every customer to have the tools to determine that process is happening for themselves.

Press Resources

Assets

Download

Contact

Abby Reisinger

[email protected]